A Non-Interventional, Multicenter, Multiple Cohort Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
A Non-Interventional, Multicenter, Multiple Cohort Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
This is a non-interventional, multi-country, multi-centre, multiple cohort prospective study, with retrospective collection of prior medical/treatment history data from medical records, designed to assess the real-world outcomes and safety of atezolizumab for indications in the existing label in the real world setting of routine clinical practice.
The study will be split into separate cohorts based on the approved indications for atezolizumab treatment, excluding cisplatin ineligible participants receiving atezolizumab as first line of therapy (LOT1) for locally advanced/metastatic urothelial cancer (locally advanced/metastatic UC). The study may be amended for inclusion of new cohorts as these are approved in the participating countries. Participants will be included into each cohort based on their indication for receiving atezolizumab.
Inclusion Criteria:
Exclusion Criteria:
CABA, C1426AGE, Argentina
Ciudad Autonoma Buenos Aires, C1199ABB, Argentina
Mont-godinne, 5530, Belgium
Varna, 9010, Bulgaria
Gachibowli, Telangana 500032, India
Shuwakh Industrial, 70653, Kuwait
Kaunas, 50009, Lithuania
?ód?, 91-520, Poland
?ód?, 93-513, Poland
Bielsko-Bia?a, 43-300, Poland
Grudzi?dz, 86-300, Poland
Wroc?aw, 53-439, Poland
Cluj-Napoca, 400162, Romania
Krasnoyarsk, Krasnodarskiy Kray 660133, Russia
Moscow, Moscow Oblast 115478, Russia
Saint Petersburg, Sankt-Peterburg 197758, Russia
Kazan', Tatarstan Republic 420029, Russia
Santiago de Compostela, LA Coruna 15706, Spain
Wiltshire, SN3 6BB, United Kingdom